- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07445763
Studie TARSILA založená na reálných datech (TARSILA)
Reálná účinnost mateřské RSVpreF vakcinace proti RSV-asociovaným akutním respiračním onemocněním u kojenců v Brazílii (studie TARSILA): multicentrická, prospektivní, test-negativní, případová kontrolní studie
The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Maicon Falavigna, MD PhD
- Telefonní číslo: +55 51 2399 1750
- E-mail: research@inovamedical.com.br
Studijní místa
-
-
Paraná
-
Cascavel, Paraná, Brazílie, 85818-130
- Nábor
- Unidade de Pronto Atendimento Veneza
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Curitiba, Paraná, Brazílie, 80060-900
- Nábor
- Complexo do Hospital de Clínicas da Universidade Federal do Paraná
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Vrchní vyšetřovatel:
- Cristina de Oliveira Rodrigues
-
Curitiba, Paraná, Brazílie, 80240-031
- Nábor
- Hospital Infantil Pequeno Príncipe
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Vrchní vyšetřovatel:
- Heloisa Ihle Garcia Giamberardino
-
Marechal Cândido Rondon, Paraná, Brazílie, 85960-000
- Nábor
- Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Palotina, Paraná, Brazílie, 85950-000
- Nábor
- Unidade de Saúde Central de Palotina
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Toledo, Paraná, Brazílie, 85902-480
- Nábor
- Unidade de Pronto Atendimento II de Toledo
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazílie, 91350-200
- Nábor
- Hospital Nossa Senhora da Conceição
-
Kontakt:
- Maicon Falavigna, PhD
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Vrchní vyšetřovatel:
- Fernanda H Varela
-
Porto Alegre, Rio Grande do Sul, Brazílie, 90035-903
- Nábor
- Hospital de Clínicas de Porto Alegre
-
Kontakt:
- Maicon Falavigna
- Telefonní číslo: +555123991750
- E-mail: research@inovamedical.com.br
-
Vrchní vyšetřovatel:
- Ricardo Becker Feijó
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Infants with acute respiratory illness (ARI)
Popis
Tarsila Inpatient Study
Inclusion Criteria
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Maternal or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Infant previously enrolled in this study.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
Tarsila Outpatient Study
Inclusion Criteria:
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Mother or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
- Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: CASE_CONTROL
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Cases
Infants with a positive respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
|
Controls
Infants with a negative respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing). |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Časové okno: Occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring). |
Occurring ≤180 days after birth.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) . |
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Časové okno: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness. |
ARI occurring ≤180 days after birth
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization. |
Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
|
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) . |
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
RT-qPCR-confirmed RSV-positive LRTD in-hospital death. |
Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
|
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization. |
Hospitalization occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Časové okno: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed HMPV-positive LRTD hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Časové okno: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by:
|
ARI occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Časové okno: ARI occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness. |
ARI occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Časové okno: LRTD occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤180 days after birth.
|
|
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Časové okno: LRTD occurring ≤360 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤360 days after birth.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Maicon Falavigna, Inova Medical
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- CAAE 95166426.7.1001.0008
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .